

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



June 29, 2026

Company name TSUZUKI DENKI CO., LTD.
Representative Katsuyuki Yoshida
Representative Director, President & CEO
Securities code 8157 (TSE Prime Market)
Contact Toshihiro Hirai
Managing Executive Officer
(Tel: +81-50-3684-7780)

Matters concerning controlling shareholders, etc.

We hereby announce matters concerning the controlling shareholder, in connection with other affiliated company, ASO CORPORATION.

1. Names of other affiliated companies, etc.

(As of March 31, 2026)

Name	Attribute	Ratio of voting rights (%)			Financial instruments exchanges, etc. where its shares are listed
		Direct ownership	Combined ownership	Total	
ASO CORPORATION	Other affiliated company	24.03	—	24.03	—

2. The position of the listed company within the corporate group of the parent company, etc. and the relationship between other listed company and the parent company, etc.

(1) Our position within the corporate group of the parent company.

Aso Corporation holds 24.03% of our voting rights, and we are an equity-method affiliate of the company. The Aso Group has entered into a capital and business alliance agreement aimed at creating services that help solve the challenges faced by various industries, in collaboration with its 'medical and nursing-related businesses', 'information and software businesses', 'construction and civil engineering businesses', and 'human resources and education businesses', thereby further enhancing the company's corporate value.

(2) Human relationships with parent companies, etc.

Post	Name	Position at parent company or group company	Reasons for appointment
External Director	Hidetoshi Takinaka	Representative Director and Vice President, ASO CORPORATION	As the president and representative director of Aso Information Systems Co., Ltd., a consolidated subsidiary of Aso Corporation, possess deep insights into the medical and caregiving industries through extensive experience and achievements. Therefore, he can be expected to provide supervision and advice in the company's future challenges in new fields and areas of growth.

3. Matters concerning transactions with controlling shareholders, etc.

There are no significant transactions to be disclosed for the fiscal year ending in March 2026.